FPR3 (Gene)

Organism:

Homo sapiens

Synonyms:ENTREZ:2359, FML2_HUMAN, FMLP-R-II, FMLPY, FPR3, FPRH1, FPRH2, FPRL2, HGNC:3828, MIM:136539, NM_002030, NP_002021, RMLP-R-I, XM_011526687, XP_011524989, formyl peptide receptor 3

Id:ENSG00000187474

Entrez:2359

Ensembl:ENSG00000187474

Description:formyl peptide receptor 3

Predicted to enable N-formyl peptide receptor activity and complement receptor activity. Predicted to be involved in several processes, including complement receptor mediated signaling pathway; phospholipase C-activating G protein-coupled receptor signaling pathway; and positive regulation of cytosolic calcium ion concentration. Predicted to act upstream of or within G protein-coupled receptor signaling pathway. Predicted to be integral component of membrane. Predicted to be active in plasma membrane. [provided by Alliance of Genome Resources, Apr 2022]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View FPR3's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with FPR3.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using FPR3.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for FPR3.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with FPR3.

Results found

Linked to

	Label	Description
	GSE77108 saha 4 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE151612 4 V 2 PRACINOSTAT HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE233679 5 V 15 NICOTINAMIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE77108 8 V 7 SAHA HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE119007 prostaglandin TS-A clone E2 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE233679 nicotinamide 14 v 15 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 4 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE193351 ruxolitinib 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE189035 inositol 2 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE228106 3 V 2 PACLITAXEL HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS

GSE77108 saha 4 v 7 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE151612 4 V 2 PRACINOSTAT HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE233679 5 V 15 NICOTINAMIDE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE77108 8 V 7 SAHA HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE119007 prostaglandin TS-A clone E2 1 v 0 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE233679 nicotinamide 14 v 15 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 4 v 11 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE193351 ruxolitinib 1 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE189035 inositol 2 v 7 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE228106 3 V 2 PACLITAXEL HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.